AbbVie Inc.
Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
Last updated:
Abstract:
The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
Status:
Grant
Type:
Utility
Filling date:
4 Nov 2020
Issue date:
29 Mar 2022